telehealth glp 1 Were you getting GLP-1 weight-loss medications through an online company like Hims, Hers, or another platform? If those services are now paused or limited, you don't have to stop your care Patientory Wallet launches telehealth service

Description

A critical review of the literature

Since their discovery, GLP-1 receptor agonists have been considered a good treatment option mainly because of their favorable effect on glycemic control, which can sometimes be challenging to achieve

Executive Summary Quick Insight: The GLP-1 Weight Loss Drug Market is on track to more than double to USD 192 billion by 2035 , driven by explosive patient demand for injectable and oral incretin therapies, multi-indication label expansion beyond obesity into cardiovascular protection and metabolic disease management, a robust late-stage pipeline of next-generation triple agonists, and unprecedented payer engagement transforming obesity into a fully reimbursable chronic disease requiring long-term pharmacological management

doi: 10.1016/j.cmet.2021.12.010 Summary Keywords GIP, GLP-1, obesity, weight loss, tirzepatide, GLP-1R agonists, GIP receptor agonists, Citation Zaffina I, Pelle MC, Armentaro G, Giofr F, Cassano V, Sciacqua A and Arturi F (2023) Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity